We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Early Serum Creatinine Predicts Post-Surgery AKI

By LabMedica International staff writers
Posted on 05 Apr 2017
Print article
Image: The Combur 10 urinalysis test strips (Photo courtesy of Roche).
Image: The Combur 10 urinalysis test strips (Photo courtesy of Roche).
Acute Kidney Injury (AKI) is a common and serious complication of cardiac surgery. Mild AKI occurs in nearly one in five patients undergoing cardiac surgery and is associated with a 19-fold increase in short-term mortality.

It is important to identify patients who are at risk of developing AKI post cardiac surgery as historically and again recently, it has been shown that early nephrology referral for patients who develop AKI results in improved outcomes.

Scientists at the Monash Medical Centre and their colleagues prospectively studied 196 consecutive patients undergoing elective (on-pump) cardiac surgery. All patients undergoing on pump cardiac surgery had urinalysis for proteinuria and serum urea and creatinine determined within one month prior to surgery. The study population was predominantly male (73.5%) with the median age of enrolled participants being 70.8 years (range 30–91).

Serum urea and creatinine were subsequently collected immediately upon arrival to intensive care unit (ICU), within two hours of surgery completion, daily for 48 hours, and prior to discharge. Urinalysis was performed using Roche Combur 10 Test Strips and proteinuria was graded according to severity ranging from no detectable protein at 0 to a maximum score of 3 as annotated on the urinalysis kit. Subjects were classified as having proteinuria if the test strip score was 1 or higher.

The scientists reported that the mean pre-operative creatinine was 86 μmmol/L (range 40–246; SD 27.0) with a mean eGFR of 75.63 mL/min/1.73 m2 (range 21.59–118.8 ± 18.75) and 19% of the cohort had diabetes and 40 (20.4%) patients developed AKI postoperatively. Hypertension (OR 2.64), diabetes (OR 2.25), proteinuria (OR 2.48), and a lower baseline eGFR (OR 0.74) were associated with AKI in univariate analysis. A fall of greater than 15% from baseline in the early post-operative serum creatinine was protective for the development of AKI (OR = 0.34). On its own, the change in early post-operative serum creatinine was poorly predictive for AKI.

The authors concluded that a rise of greater than 15% in serum creatinine (sCr) over baseline, taken within two hours of arrival to ICU, equated to an odds ratio of seven for the development of AKI. This is important as sCr is an inexpensive, readily available test and measurements of early sCr could easily be incorporated into clinical practice, even in resource poor settings. They suggest that patients who demonstrate an increase in early sCr should be referred to a nephrologist in a timely manner. This would enable early interventions and potentially improve outcomes. The study was published on March 16, 2017, in the journal BMC Nephrology.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.